Moreover, analysis performed using samples from breast cancer patients showed that the clonogenic assay predicted the clinical response toward several agents [14], indicating the potential of ramentaceone in HER2-positive breast cancer therapy. This evidence concerns the gene ERBB2 and breast carcinoma.